Safety and Pharmacodynamics of SEL-212 (Pegsiticase + SEL-110) in Subjects With Elevated Blood Uric Acid Levels
Clinical trial NCT02648269 · COMPLETED
Trial details
- NCT number
- NCT02648269
- Sponsor
- Selecta Biosciences, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2015-12-01
- Primary completion
- 2016-12-01
- Enrollment
- 63
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.